Showing results (3791-3800 of 10,080) with videos related to
Sort By:
Pageof 1,008
Current Pharmaceutical Design|January 20, 2009
CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditionsEduardo Nunes ChiniCurrent Pharmaceutical Design|January 20, 2009
The evolution of schizophrenia: a model for selection by infection, with a focus on NADChristine L MillerCurrent Pharmaceutical Design|January 20, 2009
Nuclear medicine: proof of principle for targeted drugs in diagnosis and therapyThomas LeithaCurrent Pharmaceutical Design|January 20, 2009
Targeted therapies in solid tumours: pinpointing the tumour's Achilles heelGabriela Kornek, Edgar SelzerCurrent Pharmaceutical Design|January 20, 2009
Non-invasive methods and techniques for central blood pressure estimation: procedures, validation, reproducibility and limitationsTheodore G Papaioannou, Athanassios D Protogerou, Kimon S Stamatelopoulos, et al.Current Pharmaceutical Design|January 20, 2009
The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II: Evidence for specific class-effects of antihypertensive drugs on pressure amplificationAthanase D Protogerou, George S Stergiou, Charalambos Vlachopoulos, et al.Current Pharmaceutical Design|January 20, 2009
Red wine, arterial stiffness and central hemodynamicsKalliopi Karatzi, Theodore G Papaioannou, Christos Papamichael, et al.Current Pharmaceutical Design|July 30, 2004
Molecular and cellular mechanisms in the pathophysiology of severe head injuryP Enriquez, R BullockCurrent Pharmaceutical Design|July 30, 2004
Importance of aquaporins in the physiopathology of brain edemaJosé L Venero, Alberto Machado, Josefina CanoCurrent Pharmaceutical Design|July 30, 2004
Moderate hypothermia in the management of severe traumatic brain injury: a good idea proved ineffective?J Sahuquillo, M P Mena, A Vilalta, et al.Pageof 1,008